Velikova, G., Morden, J. P., Haviland, J. S., Emery, C., Barrett-Lee, P., Earl, H., …Cameron, D. (in press). Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncology, S1470-2045(23)00460-6. https://doi.org/10.1016/S1470-2045%2823%2900460-6